These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34390764)

  • 1. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.
    Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X
    Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
    Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
    Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
    Mark C; Warrick J; Callander NS; Hematti P; Miyamoto S
    Mol Cancer Res; 2022 Sep; 20(9):1456-1466. PubMed ID: 35604822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
    Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
    Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
    Huynh M; Pak C; Markovina S; Callander NS; Chng KS; Wuerzberger-Davis SM; Bakshi DD; Kink JA; Hematti P; Hope C; Asimakopoulos F; Rui L; Miyamoto S
    J Biol Chem; 2018 Feb; 293(7):2452-2465. PubMed ID: 29279332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
    Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
    Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
    Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
    Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
    Chauhan D; Li G; Podar K; Hideshima T; Shringarpure R; Catley L; Mitsiades C; Munshi N; Tai YT; Suh N; Gribble GW; Honda T; Schlossman R; Richardson P; Sporn MB; Anderson KC
    Blood; 2004 Apr; 103(8):3158-66. PubMed ID: 15070698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
    Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
    Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfiram/copper targets stem cell-like ALDH
    Jin N; Zhu X; Cheng F; Zhang L
    J Cell Biochem; 2018 Aug; 119(8):6882-6893. PubMed ID: 29665144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
    Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
    Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway.
    Song IS; Jeong YJ; Nyamaa B; Jeong SH; Kim HK; Kim N; Ko KS; Rhee BD; Han J
    BMB Rep; 2015 Oct; 48(10):571-6. PubMed ID: 25772758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
    Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
    Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.